Orili 200 mg (Tablet)
Unit Price: ৳ 235.00 (2 x 6: ৳ 2,820.00)
Strip Price: ৳ 1,410.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Elagolix sodium |
| Company | Square pharmaceuticals plc |
| Also available as |
Indications
- For the management of moderate to severe pain associated with endometriosis
Pharmacology
- GnRH receptor antagonist
- Inhibits endogenous GnRH signaling
- Competitively binds to GnRH receptors
- Results in suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH)
- Leads to decreased blood concentrations of estradiol and progesterone
Dosage & Administration
- Pregnancy exclusion before starting treatment
- Initial treatment with Elagolix 150 mg
- Initial treatment with Elagolix 200 mg
- Duration of treatment based on hepatic impairment
- Use in children and adolescents not established
Interaction
- May potentiate P-gp substrates (e.g. digoxin)
- May antagonize CYP3A substrates
- Reduced efficacy with estrogen-containing contraceptives
- No known food interaction
Contraindications
- Contraindicated in pregnant women
- Contraindicated with known osteoporosis
- Contraindicated for severe hepatic impairment
- Contraindicated with concomitant use of strong organic anion transporting polypeptide OATP1B1 inhibitors
Side Effects
- Common: hot flushes, night sweats, headache, nausea, amenorrhea, arthralgia, mood changes, bone loss
- Rare: Insomnia, anxiety, elevated hepatic transaminase
Pregnancy & Lactation
- Use is contraindicated in pregnant women
- Discontinue if pregnancy occurs during treatment
- No information on effects on breastfed child or milk production
Precautions & Warnings
- Dose-dependent decreases in bone mineral density
- Reduced ability to recognize pregnancy
- Suicidal ideation and mood disorders
- Hepatic transaminase elevations
- Potential for reduced efficacy with estrogen-containing contraceptives
Use in Special Populations
- No dose adjustment in women with renal impairment or end-stage renal disease
- No dosage adjustment in women with mild hepatic impairment
- Safety and effectiveness not established in patients less than 18 years of age
Overdose Effects
- Patients should be monitored for signs or symptoms of adverse reactions and initiate appropriate treatment
Therapeutic Class
- Gonadotropin-releasing hormone (GnRH) antagonist
Storage Conditions
- Store in a cool & dry place
- Protect from light & moisture
- Keep out of reach of children